Abstract
The p38 mitogen-activated protein (MAP) kinase plays a central role in inflammation. It has been the subject of extensive efforts in both basic research and drug discovery for the treatment of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where aberrant cytokine signaling is the driver of the disease. This article reviews the patent and journal publication activities during 2006-2008 describing novel small molecule p38α inhibitors.
Keywords: mitogen-activated protein (MAP), p38, Kinase Inhibitors, inflammation, rheumatoid arthritis, cytokine, bowel disease
Current Topics in Medicinal Chemistry
Title: Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008
Volume: 8 Issue: 16
Author(s): Liping H. Pettus and Ryan P. Wurz
Affiliation:
Keywords: mitogen-activated protein (MAP), p38, Kinase Inhibitors, inflammation, rheumatoid arthritis, cytokine, bowel disease
Abstract: The p38 mitogen-activated protein (MAP) kinase plays a central role in inflammation. It has been the subject of extensive efforts in both basic research and drug discovery for the treatment of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, where aberrant cytokine signaling is the driver of the disease. This article reviews the patent and journal publication activities during 2006-2008 describing novel small molecule p38α inhibitors.
Export Options
About this article
Cite this article as:
Pettus H. Liping and Wurz P. Ryan, Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008, Current Topics in Medicinal Chemistry 2008; 8 (16) . https://dx.doi.org/10.2174/156802608786264245
DOI https://dx.doi.org/10.2174/156802608786264245 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
S100A9 Exacerbates the Aβ1-42-mediated Innate Immunity in Human THP-1 Monocytes
CNS & Neurological Disorders - Drug Targets Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
Current Medicinal Chemistry Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design The Axis of Thrombospondin-1, Transforming Growth Factor Beta and Connective Tissue Growth Factor: An Emerging Therapeutic Target in Rheumatoid Arthritis
Current Vascular Pharmacology Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design Painful Peripheral Neuropathies
Current Neuropharmacology Citrullinated Peptides in the Diagnosis of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry COX-2 Inhibition, H. pylori Infection and the Risk of Gastrointestinal Complications
Current Pharmaceutical Design NPY and Receptors in Immune and Inflammatory Diseases
Current Topics in Medicinal Chemistry Novel Insights into the Pathogenesis of Osteoarthritis
Current Rheumatology Reviews Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Epigenetics and Periodontal Disease: Hope to Tame the Untameable
Current Gene Therapy Integrin Antagonists: A Special Emphasis on Structural Requirements of N-benzoyl-L-biphenylalanines as α4β7 and α4β1 Antagonists
Current Signal Transduction Therapy Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery The Treatment of Wrist Osteoarthritis, SLAC Wrist Grade 3-4
Current Rheumatology Reviews